Literature DB >> 9915035

Progress toward elimination of hepatitis B virus transmission in the United States.

E E Mast1, F J Mahoney, M J Alter, H S Margolis.   

Abstract

The strategy to eliminate hepatitis B virus (HBV) transmission in the United States is comprised of the following components: (1) preventing perinatal transmission, (2) routine infant vaccination, (3) catch-up vaccination of children in high-risk groups at any age, (4) catch-up vaccination of all children at 11-12 years of age and (5) vaccination of adolescents and adults in high-risk groups. According to recent surveys, > 85% of pregnant women are screened for hepatitis B surface antigen (HBsAg). Of infants born to HBsAg-positive women identified in 1995, 93% received appropriate immunoprophylaxis at birth; however, only 69% were fully vaccinated by 6-8 months of age. From 1991 (when routine infant hepatitis B vaccination was first recommended) to 1996, the proportion of 19-35-month-old children who have received three doses of hepatitis B vaccine has increased from < 10 to 83%. During this time, rates of acute hepatitis B in children 7-10 years of age have declined by 27% and rates among children 3-6 years of age have declined by 62%. Implementation of programmes for catch-up vaccination of all adolescents at 11-12 years of age and for vaccination of adolescents and adults in high-risk groups have only recently begun and no data are available to assess the progress of these programmes. However, 26% (13/50) of states now have laws requiring adolescents to be vaccinated in order to enter school. Current data indicate that substantial progress has been made in implementing a strategy to eliminate HBV transmission in the United States. Future efforts need to be focused on improving complete immunoprophylaxis of infants of HBsAg-positive mothers, increasing vaccine coverage among 11-12 year old children and implementing programmes to vaccine adolescents and adults in high-risk groups.

Entities:  

Mesh:

Year:  1998        PMID: 9915035     DOI: 10.1016/s0264-410x(98)00294-1

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Comparison of the effect of two different doses of recombinant hepatitis B vaccine on immunogenicity in healthy adults.

Authors:  Jing Li; Jun Yao; Huan Shan; Yongdi Chen; Zheng-gang Jiang; Jing-jing Ren; Kai-jin Xu; Bing Ruan; Shi-gui Yang; Bing Wang; Tian-sheng Xie; Qian Li
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  The response of hepatitis B vaccination on seronegative adults with different vaccination schedules.

Authors:  Jun Yao; Jing Li; Yongdi Chen; Huan Shan; Xue-wei Dai; Lin-na Yang; Zheng-gang Jiang; Jing-jing Ren; Kai-jin Xu; Bing Ruan; Shi-gui Yang; Bing Wang; Tian-sheng Xie; Qian Li
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Immunological effects of a 10-μg dose of domestic hepatitis B vaccine in adults.

Authors:  Jing-jing Ren; Xue-wei Dai; Zheng-gang Jiang; Ling-zhi Shen; Yong-di Chen; Qian Li; Wen Ren; Ying Liu; Jun Yao; Lan-juan Li
Journal:  J Zhejiang Univ Sci B       Date:  2012-11       Impact factor: 3.066

4.  Two decades after vaccine license: hepatitis B immunization and infection among young men who have sex with men.

Authors:  D A MacKellar; L A Valleroy; G M Secura; W McFarland; D Shehan; W Ford; M LaLota; D D Celentano; B A Koblin; L V Torian; H Thiede; R S Janssen
Journal:  Am J Public Health       Date:  2001-06       Impact factor: 9.308

5.  Adherence to hepatitis B virus vaccination at syringe exchange sites.

Authors:  Frederick L Altice; Robert D Bruce; Mary R Walton; Marta I Buitrago
Journal:  J Urban Health       Date:  2005-03-03       Impact factor: 3.671

6.  Effect of hepatitis B immunoglobulin on interruption of HBV intrauterine infection.

Authors:  Xiao-Mao Li; Min-Feng Shi; Yue-Bo Yang; Zhong-Jie Shi; Hong-Ying Hou; Hui-Min Shen; Ben-Qi Teng
Journal:  World J Gastroenterol       Date:  2004-11-01       Impact factor: 5.742

7.  A case-control study of the relationship between hepatitis B virus DNA level and risk of hepatocellular carcinoma in Qidong, China.

Authors:  Tao-Tao Liu; Ying Fang; Hui Xiong; Tao-Yang Chen; Zheng-Pin Ni; Jian-Feng Luo; Nai-Qing Zhao; Xi-Zhong Shen
Journal:  World J Gastroenterol       Date:  2008-05-21       Impact factor: 5.742

8.  Multilevel factors influencing hepatitis B screening and vaccination among Vietnamese Americans in Atlanta, Georgia.

Authors:  Paula M Frew; Brooke Alhanti; Linda Vo-Green; Siyu Zhang; Chang Liu; Tranh Nguyen; Jay Schamel; Diane S Saint-Victor; Minh Ly Nguyen
Journal:  Yale J Biol Med       Date:  2014-12-12

9.  Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial.

Authors:  Chunfeng Qu; Taoyang Chen; Chunsun Fan; Qimin Zhan; Yuting Wang; Jianhua Lu; Ling-ling Lu; Zhengping Ni; Fei Huang; Hongyu Yao; Jian Zhu; Jian Fan; Yuanrong Zhu; Zhiyuan Wu; Guoting Liu; Wenhong Gao; Mengya Zang; Dongmei Wang; Min Dai; Chu Chieh Hsia; Yawei Zhang; Zongtang Sun
Journal:  PLoS Med       Date:  2014-12-30       Impact factor: 11.069

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.